Management Change/Compensation Form 8 K

Entry into Release Agreement and Consulting Agreement with Joe Bonaccorso

Consistent with Verrica Pharmaceuticals Inc.'s (the "Company") previously disclosed expectations in its Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission on August 27, 2024 (the "Earlier Form 8-K"), on August 30, 2024, the Company and Joe Bonaccorso, the Company's former Chief Commercial Officer, entered into a Release Agreement and a Consulting Agreement (each as defined in the Earlier Form 8-K).The Release Agreement and the Consulting Agreement are on the same terms as previously disclosed in the Earlier Form 8-K.

The description of the Release Agreement and the Consulting Agreement provided in the Earlier Form 8-K is not complete and is qualified in its entirety by reference to the Release Agreement and the Consulting Agreement, which the Company intends to file as exhibits to the Company's Quarterly Report on Form 10-Q forthe quarter ending September 30, 2024.